BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

281 related articles for article (PubMed ID: 20389296)

  • 1. Predictors of infliximab failure after azathioprine withdrawal in Crohn's disease treated with combination therapy.
    Oussalah A; Chevaux JB; Fay R; Sandborn WJ; Bigard MA; Peyrin-Biroulet L
    Am J Gastroenterol; 2010 May; 105(5):1142-9. PubMed ID: 20389296
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Maintenance treatment with azathioprine in ulcerative colitis: outcome and predictive factors after drug withdrawal.
    Cassinotti A; Actis GC; Duca P; Massari A; Colombo E; Gai E; Annese V; D'Albasio G; Manes G; Travis S; Porro GB; Ardizzone S
    Am J Gastroenterol; 2009 Nov; 104(11):2760-7. PubMed ID: 19623172
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The impact of thiopurines on the risk of surgical recurrence in patients with Crohn's disease after first intestinal surgery.
    Papay P; Reinisch W; Ho E; Gratzer C; Lissner D; Herkner H; Riss S; Dejaco C; Miehsler W; Vogelsang H; Novacek G
    Am J Gastroenterol; 2010 May; 105(5):1158-64. PubMed ID: 20010925
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Early postoperative complications are not increased in patients with Crohn's disease treated perioperatively with infliximab or immunosuppressive therapy.
    Colombel JF; Loftus EV; Tremaine WJ; Pemberton JH; Wolff BG; Young-Fadok T; Harmsen WS; Schleck CD; Sandborn WJ
    Am J Gastroenterol; 2004 May; 99(5):878-83. PubMed ID: 15128354
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Response to stopping azathioprine in Crohn's patients on combined treatment with infliximab].
    Martín De Carpi J; Varea V
    An Pediatr (Barc); 2009 Mar; 70(3):271-7. PubMed ID: 19409244
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Maintenance of remission among patients with Crohn's disease on antimetabolite therapy after infliximab therapy is stopped.
    Louis E; Mary JY; Vernier-Massouille G; Grimaud JC; Bouhnik Y; Laharie D; Dupas JL; Pillant H; Picon L; Veyrac M; Flamant M; Savoye G; Jian R; Devos M; Porcher R; Paintaud G; Piver E; Colombel JF; Lemann M;
    Gastroenterology; 2012 Jan; 142(1):63-70.e5; quiz e31. PubMed ID: 21945953
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Infliximab heals intestinal inflammatory lesions and restores growth in children with Crohn's disease.
    Borrelli O; Bascietto C; Viola F; Bueno de Mesquita M; Barbato M; Mancini V; Bosco S; Cucchiara S
    Dig Liver Dis; 2004 May; 36(5):342-7. PubMed ID: 15191204
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combination of cyclosporine, azathioprine and prednisolone for perianal fistulas in Crohn's disease.
    Hinterleitner TA; Petritsch W; Aichbichler B; Fickert P; Ranner G; Krejs GJ
    Z Gastroenterol; 1997 Aug; 35(8):603-8. PubMed ID: 9297775
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mucosal healing predicts sustained clinical remission in patients with early-stage Crohn's disease.
    Baert F; Moortgat L; Van Assche G; Caenepeel P; Vergauwe P; De Vos M; Stokkers P; Hommes D; Rutgeerts P; Vermeire S; D'Haens G; ;
    Gastroenterology; 2010 Feb; 138(2):463-8; quiz e10-1. PubMed ID: 19818785
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunomodulators are associated with a lower risk of first surgery among patients with non-penetrating non-stricturing Crohn's disease.
    Picco MF; Zubiaurre I; Adluni M; Cangemi JR; Shelton D
    Am J Gastroenterol; 2009 Nov; 104(11):2754-9. PubMed ID: 19584832
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Infliximab, azathioprine, or combination therapy for Crohn's disease.
    Colombel JF; Sandborn WJ; Reinisch W; Mantzaris GJ; Kornbluth A; Rachmilewitz D; Lichtiger S; D'Haens G; Diamond RH; Broussard DL; Tang KL; van der Woude CJ; Rutgeerts P;
    N Engl J Med; 2010 Apr; 362(15):1383-95. PubMed ID: 20393175
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 6-tioguanine monitoring in steroid-dependent patients with inflammatory bowel diseases receiving azathioprine.
    Roblin X; Serre-Debeauvais F; Phelip JM; Faucheron JL; Hardy G; Chartier A; Helluwaert F; Bessard G; Bonaz B
    Aliment Pharmacol Ther; 2005 Apr; 21(7):829-39. PubMed ID: 15801918
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serious infections and mortality in association with therapies for Crohn's disease: TREAT registry.
    Lichtenstein GR; Feagan BG; Cohen RD; Salzberg BA; Diamond RH; Chen DM; Pritchard ML; Sandborn WJ
    Clin Gastroenterol Hepatol; 2006 May; 4(5):621-30. PubMed ID: 16678077
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of azathioprine maintenance therapy in a group of Crohn's disease patients in China.
    Zheng JJ; Chu XQ; Shi XH; Zhou CL; Seng BW
    J Dig Dis; 2008 May; 9(2):84-8. PubMed ID: 18419641
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Randomized controlled azathioprine withdrawal after more than two years treatment in Crohn's disease: increased relapse rate the following year.
    Vilien M; Dahlerup JF; Munck LK; Nørregaard P; Grønbaek K; Fallingborg J
    Aliment Pharmacol Ther; 2004 Jun; 19(11):1147-52. PubMed ID: 15153167
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term maintenance treatment of moderate-to-severe plaque psoriasis with infliximab in combination with methotrexate or azathioprine in a retrospective cohort.
    Dalaker M; Bonesrønning JH
    J Eur Acad Dermatol Venereol; 2009 Mar; 23(3):277-82. PubMed ID: 19207642
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Predictors of efficacy, mucosal healing and dose intensification during the first year of adalimumab therapy in patients with luminal and fistulizing Crohn's disease. National data from Hungary].
    Kiss LS; Szamosi T; Molnár T; Miheller P; Lakatos L; Vincze A; Palatka K; Bartha Z; Gasztonyi B; Salamon A; Horváth G; Tóth GT; Farkas K; Banai J; Tulassay Z; Nagy F; Szenes M; Veres G; Lovász BD; Végh Z; Golovics PA; Szathmári M; Papp M; Lakatos PL
    Orv Hetil; 2011 Sep; 152(36):1433-42. PubMed ID: 21865144
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Demographic and clinical parameters influencing the short-term outcome of anti-tumor necrosis factor (infliximab) treatment in Crohn's disease.
    Vermeire S; Louis E; Carbonez A; Van Assche G; Noman M; Belaiche J; De Vos M; Van Gossum A; Pescatore P; Fiasse R; Pelckmans P; Reynaert H; D'Haens G; Rutgeerts P;
    Am J Gastroenterol; 2002 Sep; 97(9):2357-63. PubMed ID: 12358256
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunosuppression in inflammatory bowel disease: traditional, biological or both?
    Van Assche G; Vermeire S; Rutgeerts P
    Curr Opin Gastroenterol; 2009 Jul; 25(4):323-8. PubMed ID: 19417645
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Management of Crohn's disease of the ileoanal pouch with infliximab.
    Colombel JF; Ricart E; Loftus EV; Tremaine WJ; Young-Fadok T; Dozois EJ; Wolff BG; Devine R; Pemberton JH; Sandborn WJ
    Am J Gastroenterol; 2003 Oct; 98(10):2239-44. PubMed ID: 14572574
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.